These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2360915)

  • 1. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Effects on lipoprotein composition, lipase activities and the plasma lipid fatty acid spectrum.
    Vessby B; Lithell H
    Atherosclerosis; 1990 May; 82(1-2):137-43. PubMed ID: 2360915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D; Oschry Y; Fainaru M; Eisenberg S
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
    Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
    Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
    Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
    Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
    Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
    J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparate effects of a triglyceride lowering diet and of bezafibrate on the HDL system: a study in patients with hypertriglyceridaemia and low HDL-cholesterol levels.
    Arnon R; Sehayek E; Eisenberg S
    Eur J Clin Invest; 1993 Aug; 23(8):492-8. PubMed ID: 8405002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.
    Purnell JQ; Zambon A; Knopp RH; Pizzuti DJ; Achari R; Leonard JM; Locke C; Brunzell JD
    AIDS; 2000 Jan; 14(1):51-7. PubMed ID: 10714567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of hypertriglyceridemia in the coconut oil/cholesterol-fed rabbit. Increased secretion and decreased catabolism of very low density lipoprotein.
    Van Heek M; Zilversmit DB
    Arterioscler Thromb; 1991; 11(4):918-27. PubMed ID: 2065043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding.
    de Man FH; de Beer F; van der Laarse A; Jansen H; Leuven JA; Souverijn JH; Vroom TF; Schoormans SC; Fruchart JC; Havekes LM; Smelt AH
    Atherosclerosis; 2000 Dec; 153(2):363-71. PubMed ID: 11164425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase.
    Pacy PJ; Mitropoulos KA; Venkatesan S; Watts GF; Reeves BE; Halliday D
    Atherosclerosis; 1993 Nov; 103(2):231-43. PubMed ID: 8292098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
    Wang CS; Alaupovic P; Gregg RE; Brewer HB
    Biochim Biophys Acta; 1987 Jul; 920(1):9-19. PubMed ID: 3109493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
    Vessby B; Lithell H; Ledermann H
    Atherosclerosis; 1982 Jul; 44(1):113-8. PubMed ID: 7115473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
    Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
    J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
    Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
    J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
    Vessby B; Lithell H; Hellsing K; Ostlund-Lindqvist AM; Gustafsson IB; Boberg J; Ledermann H
    Atherosclerosis; 1980 Oct; 37(2):257-69. PubMed ID: 7000090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.